Sepideh Tarbali; Shiva Khezri
Volume 22, Issue 5 , November and December 2015, , Pages 815-822
Abstract
Background: Depression is the most common psychological symptoms in multiple sclerosis (MS) patients. The exact cause of the high rate of depression in these patients is unknown, and a combination of neurological factors, including the loss of nerves coverage and psychosocial are involved. The hippocampus ...
Read More
Background: Depression is the most common psychological symptoms in multiple sclerosis (MS) patients. The exact cause of the high rate of depression in these patients is unknown, and a combination of neurological factors, including the loss of nerves coverage and psychosocial are involved. The hippocampus is extremely vulnerable to neurological diseases and has an important role in mood disorders such as depression. This study aimed to determine the effects of vitamin D3 on improving depression was conducted in an experimental model of MS.
Materials and Methods: For demyelination induction, 2µl lysolecithin was injected streotaxically into the CA1 area of hippocampus in male rat. Animals treated with vitamin D3, received 5μg/kg vitamin D3 for 7, 14 and 21 days post lesion with intraperitoneal injection. The forced swimming test was applied to determine the depression.
Results: Administration of lysolecithin as the inducer of MS disease caused demyelination and depression. In lysolecithin treated animals the immobility time as an indicator of depression in the forced swimming test on 14 day and 21 day post lesion showed a significant increase compared to the control group. While the administration of vitamin D3 for 14 and 21 days caused improvement of depression compared to the group receiving lysolecithin alone.
Conclusion: It seems prescribing of vitamin D3 at dose of 5μg/kg can improve depression in an experimental model of MS. However, evaluation of effects of vitamin D3 on the depression in MS patients, requires much more extensive studies.